Business Pfizer Lyme disease vaccine fails trial, company to seek FDA approval Finance News Mar 23, 2026 Thomas Fuller | Nurphoto | Getty ImagesPfizer on Monday said it will seek regulatory approval for a Lyme disease… Read More...
Politics India is launching cheap, weight-loss drugs and Novo Nordisk is betting on Finance News Mar 23, 2026 The Novo Nordisk logo is seen with tablets, capsules, and syringes in this photo illustration in Brussels, Belgium,… Read More...
Politics Eli Lilly’s obesity drug retatrutide clears late-stage diabetes trial Finance News Mar 19, 2026 The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025.Mike Blake |… Read More...
Politics Icotyde psoriasis pill from J&J to rival Tremfya Skyrizi IL-23 shots Finance News Mar 18, 2026 Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025.Kyle Grillot |… Read More...
Politics Zealand stock falls 35% after trial setback, CEO remains optimistic Finance News Mar 6, 2026 Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for specifically for chronic weight… Read More...
Politics Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly Finance News Mar 2, 2026 Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production… Read More...
Politics These 4 charts show the scale of Novo Nordisk’s woes Finance News Feb 25, 2026 Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe's most valuable company.But… Read More...
Business Eli Lilly launches Zepbound obesity drug pen with one month of doses Finance News Feb 23, 2026 An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024.Shelby… Read More...
Politics Novo Nordisk stock falls as weight loss drug fails to beat Eli Lilly Finance News Feb 23, 2026 The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, Nov. 5, 2025. Nichlas Pollier | Bloomberg |… Read More...